HIMS Stock Price Today (October 2026) — Hims & Hers Health, Inc. Analysis & Key Metrics 2026-10-08
Hims & Hers Health, Inc. (HIMS) is trading at $28.06, down 5.01% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $31.23 (11.3% upside).
- Volatility is high (44.34% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (38.20% YoY) alongside competitive pressures in the Drug Manufacturers - Specialty & Generic space.
HIMS Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Hims & Hers Health, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $7.25B
P/E Ratio
Forward P/E: 29.51
Revenue Growth
Year over Year
Analyst Target
+11.3% upside potential
Key Investor Questions About HIMS
What investors need to know before buying
Based on current market data, HIMS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 42.94)
- Fundamentals say: Caution warranted (high leverage concerns)
HIMS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HIMS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $1.55B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, HIMS stock traded between $13.74 and $65.30 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 44.34% annualized volatility and β=2.62, the stock exhibits high sensitivity to market moves—making HIMS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Hims & Hers Health (HIMS) Unveils AI Native Weight Loss Care Platform
Hims & Hers Health (NYSE:HIMS) introduced an AI native weight loss care platform built around a closed loop clinical system. The new offering uses continuous learning, real time monitoring, and automation to support clinician decisions within the weight loss program. Management positions the platform as a way to scale weight management services while aiming to keep safety controls embedded in workflows. The AI native weight loss care launch matters, but investors also need to weigh other...
Why Hims & Hers Health (HIMS) Is Back In The Spotlight
Hims & Hers Health (HIMS) has been in the spotlight after a class action lawsuit and related regulatory complaints over data privacy and billing practices, raising fresh questions for investors about risk, governance, and long term business quality. Despite the legal headlines, Hims & Hers Health has seen mixed momentum, with the share price up 5.11% over the last week but down 13.32% across three months. The 1-year total shareholder return has fallen 49.62% after a very large 3-year gain of...
2 Reasons to Like HIMS (and 1 Not So Much)
The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 40.2%, hitting $29.23 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
Hims & Hers Health shares fell 6.7% amid an FTC lawsuit over privacy and billing practices, a new securities class action, and a Q2 earnings miss that has weighed on the stock in 2026.
Is the Market Right or Wrong About These 4 High Short Interest Stocks?
HIMS, ONDS, COIN, and SOFI show elevated short interest, but days-to-cover ratios, institutional ownership, and upcoming earnings reports suggest differing outlooks for short sellers.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $28.39, moving 6.7% from the previous trading session.
Hims and Hers Is Scaling Rapidly, But Management Needs To Address The Difficult Questions
At first glance, Hims & Hers Health, Inc. (NYSE:HIMS) delivered the kind of result that investors typically reward. Revenue grew 38%, full-year guidance was increased, and the company completed an acquisition that management says positions it as the world’s leading consumer health platform. That made the quarter look like another strong growth report, although the […]
Hims & Hers Just Went Negative on Profit. Twice.
Key TakeawaysGross margin at Hims & Hers has fallen for eight straight quarters, from 79% in September 2024 to 64% in the quarter ended June 2026, even as revenue grew 40% year over year in that same latest quarter. Reported EBITDA margin turned negative in the March 2026 quarter and stayed there in June, at negative 8.
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Explore More Analysis for HIMS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 2, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is currently trading at $28.06. The RSI (14-day) is at 42.9, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $31.23 implies 11.3% upside from current levels. Volatility is high at 44.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Hims & Hers Health, Inc. (HIMS): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 29.51. The PEG ratio is 2.15, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 20.74. Price-to-Sales is 2.51. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering HIMS, the consensus price target is $31.23. This represents a 11.3% upside from the current price of $28.06. The range spans from a low target of $23.00 to a high target of $42.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Hims & Hers Health, Inc. (HIMS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Hims & Hers Health, Inc. (HIMS) investors include: 1. High volatility (44.3% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (debt-to-equity of 4.77x) which could pressure margins in a rising rate environment. 3. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 4. Elevated short interest (27.3% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Hims & Hers Health, Inc.'s (HIMS) current debt and financial health profile: Total debt stands at $1.55B. The debt-to-equity ratio is 4.77x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 0.93, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.82. The company holds $841.05M in cash and equivalents. Free cash flow is positive at $849.44M, providing a cushion for debt servicing and shareholder returns.